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The National Cancer Data Base (NCDB) contains
information on over 25 million cancer patients diagnosed
and treated in cancer centers across the USA since 1985.
The NCDB collects data on patient demographics, tumor
stage and histopathology, treatment, and outcomes on more
than 70% of the cancer cases diagnosed in the USA
annually. Reporting centers range from small community
hospitals to large academic medical centers and National
Cancer Institute (NCI)-designated Comprehensive Cancer
Centers. Since its inception in 1988 the NCDB has been
cofunded by the American College of Surgeons (ACoS)
and the American Cancer Society (ACS). The program-
matic focus of the NCDB, since its founding, has been to
support quality improvement at the local level.
The NCDB has evolved over time. Its focus has shifted
from peer-reviewed observational studies on patterns of
cancer care to the development of web-based audit and
feedback reporting tools for Commission on Cancer (CoC)-
accredited cancer programs to promote local quality
assessment and improvement initiatives. These tools
include descriptive reports that permit extensive user cus-
tomization and report-card-style reports displaying
performance rates for nationally recognized evidence-
based quality-of-care measures endorsed by the National
Quality Forum (NQF). The NCDB remains a widely rec-
ognized and valuable resource for a broad range of
investigators. Although not population based, the NCDB
reﬂects treatment patterns in a deﬁned universe of CoC-
accredited facilities that are required to maintain high-
quality hospital cancer registries as well as meet other
process standards. A number of retrospective studies have
been conducted in recent years, each spearheaded by
multidisciplinary disease site teams and supported by
NCDB analytic staff. The Health Services Research Group
at the American Cancer Society has also used the data base
to analyze disparities in care and outcomes related to
insurance status of cancer patients, resulting in a number of
publications and presentations. As a consequence, requests
to initiate studies using data from the NCDB have far
exceeded the available capacity of staff resources to sup-
port proposed projects. Anticipating a growth in the
demand for access to the data base, the NCDB is working
to develop a participant use ﬁle (PUF). The PUF will be a
Health Insurance Portability and Accountability Act (HI-
PAA)-compliant de-identiﬁed data set available to
interested investigators at CoC-accredited programs who
have the local resources, such as statistical analysts, to
conduct studies.
A review of the NCDB’s strengths, weaknesses, and
opportunities has been conducted and a framework for the
future directions of the data base has been developed. To
this end, a peer review of the NCDB was conducted in
March 2008, followed by a stakeholder summit in January
2009. Recommendations from the NCDB March 2008 peer
review centered on three critical elements of the NCDB’s
current and future activities: (1) maintenance and promo-
tion of hospital participation in the CoC accreditation
program, (2) continued emphasis on quality-improvement
initiatives, and (3) validation of the accuracy and com-
pleteness of the data reported to the NCDB. The goal of the
summit was to review and discuss the recommendations
from the 2008 NCDB peer review, determine short-,
medium-, and long-term objectives of NCDB stemming
from a staff-developed project plan, and prioritize and
develop strategies for these objectives. Summit attendees
included senior clinical staff from the ACoS and ACS,
NCDB staff, ACS Health Services Research staff, Com-
mission on Cancer leadership representing each of the CoC
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DOI 10.1245/s10434-009-0771-3standing committees, and leadership ﬁgures from other
constituent organizations such as the American Joint
Committee on Cancer (AJCC), the American College of
Surgeons Oncology Group (ACOSOG), and the NCI.
The peer-review report encouraged efforts to retain and
expand participation in the CoC accreditation program, and
emphasized that it was important for participating pro-
grams to perceive that they receive a high-value return
from their participation. The NCDB was viewed as an
integral part of the CoC, and furthermore, the development
and implementation of new quality-improvement measures
and tools through the NCDB for these cancer programs
held great potential value. A review of the accreditation
standards for cancer programs is underway, and revisions
will focus on strategies to reduce burden of participation
while increasing the value of participation. The CoC plans
to refocus new standards around performance metrics and
new mechanisms to help hospitals identify appropriate
metrics to evaluate the care provided for its patients and to
support the implementation of these quality assessment and
monitoring activities.
Many hospital and cancer program administrators use
data from the NCDB to monitor quality and compare their
performance and outcomes with those of other providers.
The extent to which NCDB can feed back aggregated data
to hospitals and offer added value in the form of reporting
tools and online access to data will help ensure hospitals’
continued involvement with the data base. Expanding the
information available to local institutions for comparative
analyses increases the value of their investment in tumor
registries. The CoC’s Cancer Program Practice Proﬁle
Reports (CP
3R) provide hospital performance rates for the
ﬁve NQF evidence-based quality of cancer care measures
for breast and colon cancer. In addition, this reporting tool
also includes a rectal cancer measure jointly developed and
speciﬁed by the CoC, the American Society of Clinical
Oncology (ASCO), and the National Comprehensive
Cancer Network (NCCN). These reports were recently
incorporated into the accreditation review process, and will
likely be expanded as new consensus measures are con-
sidered, developed, and speciﬁed. Soliciting clinical,
methodological, and statistical expertise through panels of
disease site teams will be critical as meaningful and fea-
sible measures are identiﬁed and feedback reports are made
available to CoC-accredited cancer programs
A new initiative of the NCDB is the Rapid Quality
Reporting System (RQRS). The RQRS represents a signiﬁ-
cant step toward providing timely and high-value
information to CoC-accredited programs. The RQRS per-
mits close to ‘‘clinical real-time reporting,’’ and issues alerts
well within a timeframe that will allow decisions on antici-
pated, evidence-based care to be discussed, ordered, and
provided efﬁciently and within guideline recommendations.
Users of the system are provided with rolling year-to-date
assessment reports, daily updated online alerts, and timely
comparison performance reports using the NQF cancer care
measures.WhiletheretrospectiveCP
3Rreportingmodelhas
demonstrated that linking assessment of clinical practice to
metrics utilizing cancer registry data can result in noticeable
shifts in the completeness of adjuvant therapy data in the
registries, the RQRS brings to bear an assessment and
monitoring tool closer to the time of the clinical encounter,
anditisanticipatedwilldrivehighlyreliableandtimelydata
on ambulatory care into participating hospital registry data
sets and subsequently into the NCDB.
The peer review encouraged the NCDB to engage in
methodologically sound and well-conceived data valida-
tion studies. Concerted efforts to ascertain the
representativeness of the data base were strongly encour-
aged. In addition, the panel urged that the NCDB undertake
a validation of those items reported to the NCDB that are
not collected by state or regional registries (e.g., insurance
status, secondary diagnoses used to gage comorbid disease
status, and disease recurrence) that might otherwise be
subject to routine quality control by central registries.
Currently, the NCDB manages large-scale data quality
control through use of the EDITS software package
developed under the auspices of the Centers for Disease
Control and Prevention and widely used by hospital, state,
and regional registries for over a decade. Using this soft-
ware, the NCDB conducts extensive internal logic
checking of reported cases using rules developed by the
North American Association of Central Cancer Registries
(NAACCR), in collaboration with the NCI/Surveillance,
Epidemiology, and End Results (SEER) and Centers for
Disease Control and Prevention (CDC)/National Program
of Cancer Registries (NPCR) programs. Additionally, the
CoC accreditation standards mandate clinical review of
10% of registry case abstracts. However, the results of
these reviews are self-reported and not independently
veriﬁed. Starting in 2009, the CoC has strengthened its
chart review requirements as part of the accreditation site
visit process. This includes a review of hospital charts and
registry abstracts to verify that registry data correctly
reﬂect the information documented in individual patient
records, and that the information summarizing the patient’s
medical condition, care, and participation in treatment
decision-making processes are adequately documented in
hospital records. These chart reviews by CoC site survey-
ors use the CoC CP
3R reported performance rates for the
four NQF-endorsed accountability measures for breast and
colon cancer care. These systematic reviews are intended
to (1) ensure that reported performance rates are an accu-
rate reﬂection of the care provided to patients at CoC-
accredited programs, and (2) address the concern that
hospital-based cancer registry data may not accurately
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review process focuses on the completeness and accuracy
of the reported ambulatory care. As the CoC reviews its
program standards for 2011, it is certain that an increased
focus on quality improvement will signiﬁcantly inﬂuence
the nature of surveys and that surveys will likely emphasize
validation of data reported to the NCDB rather than a
review of facility operational and structural characteristics.
Previous evaluations of the completeness and accuracy
of cancer registry data in the literature adopted comparative
chart review methodologies, and noted signiﬁcant differ-
ences between registry-reported and provider-documented
treatment information. There is early and increasing evi-
dence that methodologies to access commercial insurance
or Medicare claims data may yield accurate and efﬁcient
ways to obtain both in-patient and ambulatory therapy data.
Supplementing registry data with information available
from claims provides opportunities both to validate the
sensitivity and speciﬁcity of registry data and to elicit
greater levels of granularity with regard to treatment pro-
vided to cancer patients. Current efforts to link registry
data with administrative claims suggest that, while data on
ambulatory treatment is still underreported in cancer reg-
istries, it is more complete in contemporary data than in
earlier studies. Results from a small number of studies may
be expected in the near future.
Collaboration with other organizations actively engaged
in monitoring the clinical management of cancer patients is
an important key to supplementing and validating registry
data. The American College of Surgeons Oncology Group
(ACOSOG) now has the ability to compare data collected
prospectively through National Cancer Institute (NCI) tri-
als with data collected previously by cancer center
registries. Another possibility is an emerging pilot project
between the NCDB and the American Society of Clinical
Oncology’s (ASCO) Quality Oncology Practice Initiative
(QOPI) to explore opportunities to access information
describing outpatient delivery of systemic therapy.
The cancer program standards for CoC-accredited pro-
grams may also inﬂuence the accuracy, completeness, and
timeliness of data reported to the NCDB. Some investi-
gators have commented on the higher level of
completeness and accuracy of data when comparing CoC-
accredited cancer registries with registries located in non-
accredited centers. Evidence from the CoC CP
3R audit and
feedback reporting application, described above, indicate
that standards for abstracting timeliness may result in
truncating follow-up for some treatment information by
cancer registries. Additionally, although accreditation
standards require a 90% follow-up rate over the most
recent 5 years of abstracted data, recent NCDB analyses
have found that the cumulative lost-to-follow-up rate for
some patient cohorts approaches 25%. Such rates may limit
the types of analyses and conclusions that can be drawn
from these data. Vital status follow-up from hospital reg-
istries has not been systematically reviewed or validated,
and it appears that methods to determine vital status vary
widely between registries. Many hospital registries do not
have access to sources of vital status follow-up available to
central registries, including linkage with state vital records
and the National Death Index (NDI). A respeciﬁcation of
the follow-up activities for CoC-accredited programs is
likely with the pending review of the 2011 accreditation
standards. Additionally, collaborations with state and
regional registries supported by federal agencies to begin to
develop data-sharing policies and procedures to populate
hospital registries with vital status follow-up data from
administrative sources, as well as linkage between patient
identiﬁers and the NDI to ascertain vital status and causes
of death, will be explored.
The value of the NCDB as a national clinical surveil-
lance tool for cancer has increased signiﬁcantly since its
inception 20 years ago. Clinical analysis using the NCDB
to comment broadly on the state and variability of care
provided to cancer patients in the USA must be facilitated
and fostered. At publication, NCDB is in the closing stages
of a project to develop a participant use ﬁle (PUF) that will
contain case-level data for use by qualiﬁed investigators at
CoC-accredited cancer programs. The PUF will contain a
full complement of data items necessary to conduct a broad
range of studies. Necessary measures will be taken to de-
identify both reporting facilities and cases records in order
to be compliant with HIPAA regulations and the long-
standing business operations of the NCDB. Investigators
will be expected to have access to sufﬁcient statistical and
technical expertise to conduct their own studies.
The CoC recognizes that a balance must be struck
between maintaining and promoting as high a caliber of
clinical studies as possible, while at the same disseminating
the PUF to as broad a community of users as possible. The
NCDB PUF can be expected to evolve as experience and
expertise dictate. An incremental release strategy for the
PUF will be necessary, as the CoC assesses procedures and
policies developed to facilitate data distribution. During
this time, the usefulness and potential limitations of the
PUF dataset for clinical research, as well as the level of
documentation and staff support required to support
external investigators, will be evaluated with alpha test
investigators. It is anticipated that a limited number of
investigators from different institutions will be offered the
opportunity to participate in this alpha test, facilitating
interinstitutional dialogue and collaboration. An important
objective of the alpha test is to foster communities of
expertise and establish a core NCDB user community that
can serve as an effective reference point for future users of
the NCDB PUF.
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activities of the NCDB has evolved since its inception,
some of the potential for the NCDB to provide timely
feedback on quality of care and to provide a national
infrastructure for surveillance of patterns of care in the USA
has not been fully realized. Several initiatives, including the
RQRS, currently underway will accelerate progress towards
these objectives. Increasing emphasis on evaluating the
representativeness of patients and treatment patterns cap-
tured in the NCDB compared with all patients, and more
systematically validating collected data, will likely lead to
increasing acceptance of NCDB data in the cancer sur-
veillance and health services research communities. The
size and sophistication of the NCDB infrastructure allows
data to be collected, aggregated, and used to generate a wide
range of reports and peer-reviewed manuscripts. Leverag-
ing its unique relationship with providers through the CoC
accreditation program, the data base will continue to
establish itself as the primary source for developing and
implementing quality metrics for cancer care improvement,
and to retain and expand broad support within the clinical
community. The NCDB is clearly recognized as a valuable
resource and one that continues to position itself to maxi-
mize its value for both its contributors in CoC-accredited
cancer programs and members of the clinical, research, and
policy-making communities.
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